Schouw & Co (SCHO) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jul, 2026Executive summary
Revenue declined 7% year-over-year to DKK 34.7 billion in 2024, mainly due to lower input costs and activity levels.
EBITDA increased 3% to a record DKK 2.93 billion, reflecting effective margin management.
Cash flow from operations hit an all-time high, up 44% to DKK 2.55 billion, with net working capital reduced by DKK 450 million.
Net interest-bearing debt decreased 15% to DKK 5,376 million, with leverage well below 2x EBITDA.
Financial highlights
Dividend and share buybacks totaled DKK 644 million.
Investment level was DKK 685 million in 2024, reflecting prudent capital allocation.
Net working capital at DKK 6.77 billion, with inventories down from DKK 8.0 billion to DKK 7.2 billion.
Cash flow from operations rose 44% to DKK 2,553 million compared to 2023.
ROIC (excluding goodwill) improved by 0.2pp to 13.0%.
Outlook and guidance
2025 turnover expected in the range of DKK 33.4–35.9 billion; EBITDA guidance DKK 2.82–3.12 billion; EBIT: DKK 1,680–1,980 million.
CapEx in 2025 focused on maintenance and finalizing ongoing projects, with upgrades in Fibertex Nonwovens and slightly higher spending planned.
Most portfolio businesses expect stable or improved EBITDA in 2025, except Fibertex Personal Care, which anticipates continued challenges.
Cautiously optimistic outlook for 2025, supported by a well-invested platform and strong customer relationships.
Latest events from Schouw & Co
- Revenue and EBITDA fell, but profitability held as cost cuts and a BioMar IPO review drive strategy.SCHO
Q3 20248 Jul 2026 - EBITDA up 5% and profit before tax up 36% YoY, guidance maintained, BioMar IPO advancing.SCHO
Q1 20261 May 2026 - Record cash flow and EBITDA growth in most segments, with improved leverage and strong 2026 outlook.SCHO
Q4 20255 Mar 2026 - EBITDA guidance raised as margin gains offset revenue decline amid market headwinds.SCHO
Q2 20241 Feb 2026 - Q1 2025 revenue up 1%, EBITDA down 13%, guidance maintained, BioMar IPO prep advances.SCHO
Q1 202529 Nov 2025 - Stable Q2 with strong cash flow and narrowed guidance; segment outlooks mixed amid volatility.SCHO
Q2 202523 Nov 2025 - EBITDA rose 5% despite a 4% revenue drop, with narrowed guidance and ongoing restructuring.SCHO
Q3 202512 Nov 2025